Analyst Ratings For Consort Medical plc (LON:CSRT)
Today, Shore Capital reiterated its Hold rating on Consort Medical plc (LON:CSRT).
There are 3 Hold Ratings, 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Consort Medical plc (LON:CSRT) is Hold with a consensus target price of GBX 1,291.50 per share, a potential .
Some recent analyst ratings include
- 9/10/2018-Consort Medical plc (LON:CSRT) had its Hold rating reiterated by Shore Capital
- 11/9/2017-Consort Medical plc (LON:CSRT) had its Buy rating reiterated by Stifel Nicolaus with a GBX 1,250 price target
- 6/15/2017-Consort Medical plc (LON:CSRT) had its Buy rating reiterated by Panmure Gordon with a GBX 1,145 price target
- 6/15/2017-Consort Medical plc (LON:CSRT) had its Buy rating reiterated by Investec with a GBX 1,165 price target
- 1/23/2017-Consort Medical plc (LON:CSRT) had its Buy rating reiterated by Canaccord Genuity with a GBX 1,300 price target
About Consort Medical plc (LON:CSRT)
Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products. It also develops, formulates, and manufactures active pharmaceutical ingredients and finished dose drugs. Consort Medical plc was incorporated in 1946 and is based in Hemel Hempstead, the United Kingdom.
Recent Trading Activity for Consort Medical plc (LON:CSRT)
Shares of Consort Medical plc closed the previous trading session at 238,00 up +8,00 0,65 % with shares trading hands.
